The effect of skin care products for topical acne treatments which frequently show adverse events.

The effect of skin care products for topical acne treatments which frequently show adverse events. - The effect of skin care products for topical acne treatments

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027221

Enrollment

Registered

2017-05-02

Start date

2015-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne vulgaris

Interventions

Patients are instructed to apply the following skin care products and the topical medicine prescribed by dermatologists for 4 weeks. Patients apply Collage Cleansing Milk for removal of makeup, Collag

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acne vulgaris who has been treated with adapalene, benzyl peroxide and/or formulations including benzyl peroxide for more than 1 month.

Exclusion criteria

Exclusion criteria: 1) Patients who are pregnant or under lactation. 2) Patients whose facial condition may affect the acne treatment. 3) Patients with medical history of cosmetic allergy. 4) Patients who received unusual skin care within 4 weeks prior to the study that might affect their skin condition. 5) Patients who have applied the cosmetics aimed for acne treatment within 4 weeks prior to the study. 6) Patients who has been defined by the doctor as inappropriate.

Design outcomes

Primary

Measure	Time frame
No deteriorating of the total number of eruptions in comparison of before and after the usage of the test formula.	—

Secondary

Measure	Time frame
1) The number of non-inflammatory acne eruptions at the beginning and end of the experiments. 2) The number of papule/inflammatory eruptions at the beginning and end of the experiments. 3) Global Severity at the beginning and end of the experiments. 4) Skin observation/Subjective symptom: 5 criteria on skin observation (dryness/ erythema/ scale) and subjective symptom (irritation/ pruritus) at the beginning and end of the experiments. 5) Change in medication during this trial. 6) Skin conductance for measuring water content in stratum corneum at the beginning and end of the experiments.(examined at Akihabara Skin Clinic) 7) General evaluation of the safety and usefulness by the dermatologists at the beginning and end of the test. 8) QOL Assessment according to Skindex-16 at the beginning and end of the experiments. 9) Questionnaire for patients at the beginning and end of the experiments.	—

Measure

Time frame

1) The number of non-inflammatory acne eruptions at the beginning and end of the experiments. 2) The number of papule/inflammatory eruptions at the beginning and end of the experiments. 3) Global Severity at the beginning and end of the experiments. 4) Skin observation/Subjective symptom: 5 criteria on skin observation (dryness/ erythema/ scale) and subjective symptom (irritation/ pruritus) at the beginning and end of the experiments. 5) Change in medication during this trial. 6) Skin conductance for measuring water content in stratum corneum at the beginning and end of the experiments.(examined at Akihabara Skin Clinic) 7) General evaluation of the safety and usefulness by the dermatologists at the beginning and end of the test. 8) QOL Assessment according to Skindex-16 at the beginning and end of the experiments. 9) Questionnaire for patients at the beginning and end of the experiments.

—

Countries

Japan

Contacts

Public ContactNobukazu Hayashi

Toranomon Hospital Department of Dermatology

hayashi@toranomon.gr.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026